Spots Global Cancer Trial Database for primary peritoneal carcinoma
Every month we try and update this database with for primary peritoneal carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer | NCT00214058 | Ovarian Carcino... Primary Periton... | Carboplatin Docetaxel | 18 Years - | University of Wisconsin, Madison | |
| Study of INCB123667 in Subjects With Advanced Solid Tumors | NCT05238922 | Solid Tumors | INCB0123667 | 18 Years - | Incyte Corporation | |
| Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma) | NCT02485990 | Primary Periton... | Tremelimumab Olaparib | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients | NCT00478452 | Ovarian Cancer Fallopian Tube ... Primary Periton... | DC-Ova DC Ova with Cyc... | 18 Years - | University of Pennsylvania | |
| Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels | NCT00083928 | Ovarian Cancer Primary Periton... | Å6 subcutaneous... | 18 Years - | Ångstrom Pharmaceuticals | |
| Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi | NCT06161272 | Ovarian Cancer High Grade Sero... Primary Periton... Fallopian Tube ... | Fluzoparib Fluzoparib+Apat... | 18 Years - 75 Years | Guangxi Medical University | |
| EDMONd - Elemental Diet in Bowel Obstruction | NCT03150992 | Ovarian Cancer Ovarian Neoplas... Ovarian Disease Peritoneal Neop... Peritoneal Dise... Metastatic Ovar... Primary Periton... Abdominal Neopl... Bowel Obstructi... | Elemental 028 E... | 18 Years - 90 Years | Royal Surrey County Hospital NHS Foundation Trust | |
| Intraperitoneal Paclitaxel and Carboplatin in the Treatment of Women With Carcinoma of Mullerian Origin | NCT00181701 | Ovarian Carcino... | Paclitaxel Carboplatin | 18 Years - | Massachusetts General Hospital | |
| Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma | NCT00868192 | Ovarian Carcino... Primary Periton... | Pemetrexed Bevacizumab | 18 Years - | Washington University School of Medicine | |
| A Trial of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent or Persistent Ovarian Cancer | NCT02344095 | Epithelial Ovar... Fallopian Tube ... Primary Periton... | weekly paclitax... weekly cisplati... oncothermia | - | Seoul National University Hospital | |
| High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy | NCT04201561 | Chemotherapy-in... Recurrent Ovari... Ovarian Cancer Fallopian Tube ... Primary Periton... | sodium selenite... Normal saline Chemotherapy | 19 Years - 80 Years | Seoul National University Hospital | |
| A Study of Sovilnesib in Subjects With Ovarian Cancer | NCT06084416 | High Grade Sero... Fallopian Tube ... Primary Periton... Chromosomal Ins... | Sovilnesib | 18 Years - | Volastra Therapeutics, Inc. | |
| A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer | NCT02661815 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Paclitaxel Ricolinostat Bevacizumab | 18 Years - | Dana-Farber Cancer Institute | |
| Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer | NCT03029403 | Advanced Cancer Ovarian Cancer Primary Periton... Fallopian Tube ... | Pembrolizumab DPX-Survivac Cyclophosphamid... | 18 Years - | University Health Network, Toronto | |
| Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers | NCT02725489 | Breast Cancer Ovarian Cancer Fallopian Tube ... Primary Periton... Uterine Cancer Cervical Cancer Endometrial Can... | Vigil Durvalumab | 18 Years - | Mary Crowley Medical Research Center | |
| Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients | NCT01308944 | Invasive Epithe... Primary Periton... Fallopian Tube ... | Propranolol | 18 Years - | Washington University School of Medicine | |
| Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) | NCT02859038 | Epithelial Ovar... Fallopian Tube ... Primary Periton... | Upfront cytored... Interval debulk... | 18 Years - | Shanghai Gynecologic Oncology Group | |
| EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | NCT01118052 | Fallopian Tube ... Primary Periton... Recurrent Ovari... | Laboratory Biom... PEG-PEI-cholest... | 18 Years - | GOG Foundation | |
| Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | NCT00989651 | Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Brenner... Ovarian Carcino... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Primary Periton... Stage IIA Fallo... Stage IIA Ovari... Stage IIB Fallo... Stage IIB Ovari... Stage IIC Fallo... Stage IIC Ovari... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... | Bevacizumab Carboplatin Cisplatin Laboratory Biom... Paclitaxel Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma | NCT03608618 | Peritoneal Meso... Fallopian Tube ... Adenocarcinoma ... Primary Periton... | MCY-M11 Cyclophosphamid... | 18 Years - | MaxCyte, Inc. | |
| Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | NCT02419495 | Advanced Malign... Clinical Stage ... Clinical Stage ... Fallopian Tube ... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Rena... Ovarian Carcino... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Primary Periton... Stage III Lung ... Stage III Renal... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IV Renal ... Stage IVA Lung ... Stage IVB Lung ... Triple-Negative... Unresectable Lu... Unresectable Me... Unresectable Re... | Capecitabine Carboplatin Cyclophosphamid... Doxorubicin Eribulin Fluorouracil Ipilimumab Irinotecan Hydr... Leucovorin Calc... Nivolumab Olaparib Oxaliplatin Paclitaxel Pembrolizumab Pemetrexed Selinexor Topotecan | 18 Years - | M.D. Anderson Cancer Center | |
| Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma | NCT01519869 | Primary Periton... Ovarian Carcino... Fallopian Tube ... | neoadjuvant che... | 18 Years - | University of Kentucky | |
| Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer | NCT00551070 | Borderline Ovar... Low Grade Ovari... Micropapillary ... Primary Periton... Primary Periton... Recurrent Borde... | Laboratory Biom... Pharmacological... Selumetinib Selumetinib Sul... | 19 Years - | National Cancer Institute (NCI) | |
| Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for Advanced or Recurrent Disease | NCT01588522 | Breast Cancer Cervical Cancer Endometrial Can... Ovarian Cancer Primary Periton... Bone Sarcoma Cancer Solid Tumor | compound 31543 ... | 18 Years - | Berg, LLC | |
| A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian | NCT01952249 | Primary Periton... | Demcizumab Taxol | 21 Years - 90 Years | Mereo BioPharma | |
| Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer | NCT00072566 | Primary Periton... Recurrent Ovari... Stage IV Ovaria... | Bevacizumab Cyclophosphamid... Laboratory Biom... | - | National Cancer Institute (NCI) | |
| SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care | NCT04368130 | Ovarian Cancer Fallopian Tube ... Primary Periton... Uterine Cancer Cervical Cancer Gynecologic Can... | SIGNAL | 18 Years - | Dana-Farber Cancer Institute | |
| Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women | NCT01227928 | Neoplasms, Ovar... | Pazopanib Placebo compara... | 18 Years - | GlaxoSmithKline | |
| RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression | NCT06420973 | Ovarian Carcino... Fallopian Tube ... Primary Periton... | RC48+carboplati... | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | NCT05199272 | Solid Tumor Clear Cell Rena... Epithelial Ovar... Fallopian Tube ... Primary Periton... Neuroendocrine ... MSI-H Cancer Cancer With A H... Extensive-stage... | 23ME-00610 | 12 Years - | 23andMe, Inc. | |
| European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer | NCT03783949 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Ganetespib Niraparib Carboplatin Paclitaxel Gemcitabine | 18 Years - | Universitaire Ziekenhuizen KU Leuven | |
| Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer | NCT02788708 | Fallopian Tube ... Recurrent Ovari... Primary Periton... Recurrent Endom... | Lenvatinib Mesy... Paclitaxel Pharmacological... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | NCT03602079 | HER2-positive B... HER2 Gene Mutat... HER-2 Gene Ampl... HER2 Positive G... Salivary Gland ... Salivary Gland ... Salivary Gland ... Salivary Gland ... Lung Cancer Colo-rectal Can... Rare Diseases Solid Tumor Recurrent Gastr... Recurrent Colon... Recurrent Breas... Head and Neck C... Head and Neck C... Bladder Cancer Cervical Cancer Liver Cancer Bile Duct Cance... Urologic Cancer Pancreatic Canc... Prostate Cancer Recurrent Prost... Rectal Cancer Recurrent Ovari... Recurrent Renal... Rectal Cancer S... Rectal Cancer S... Rectal Cancer S... Skin Cancer Mouth Cancer Lip Cancer Stag... Tongue Cancer Breast Neoplasm... Larynx Cancer Tonsil Cancer Palate Cancer Mucoepidermoid ... Primary Periton... Mucinous Adenoc... Mucinous Breast... Cholangiocarcin... | A166 | 18 Years - | Klus Pharma Inc. | |
| Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial | NCT01506856 | Epithelial Ovar... Fallopian Tube ... Primary Periton... | Paclitaxel(intr... Paclitaxel(intr... | 20 Years - | Gynecologic Oncology Trial & Investigation Consortium | |
| Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer | NCT02345265 | Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Carcino... Ovarian High Gr... Ovarian High Gr... Primary Periton... Primary Periton... Primary Periton... | Biopsy Biospecimen Col... Cediranib Malea... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Olaparib Questionnaire A... | 18 Years - | National Cancer Institute (NCI) | |
| Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for Advanced or Recurrent Disease | NCT01588522 | Breast Cancer Cervical Cancer Endometrial Can... Ovarian Cancer Primary Periton... Bone Sarcoma Cancer Solid Tumor | compound 31543 ... | 18 Years - | Berg, LLC | |
| Fermented Wheat Germ Extract in Women With Ovarian Cancer | NCT02411565 | Ovarian Cancer | Fermented Wheat... Placebo Standard of Car... Quality of Life... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer | NCT03783949 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Ganetespib Niraparib Carboplatin Paclitaxel Gemcitabine | 18 Years - | Universitaire Ziekenhuizen KU Leuven | |
| Study of Ramucirumab in Ovarian Cancer | NCT00721162 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Ramucirumab | 18 Years - | Eli Lilly and Company | |
| A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE) | NCT05429970 | Ovarian Cancer Ovarian Carcino... Stage II Ovary ... Stage II Ovaria... Stage III Ovary... Stage III Ovari... Stage IV Ovary ... Stage IV Ovaria... Epithelial Ovar... Fallopian Tube ... Stage II Fallop... Stage III Fallo... Stage IV Fallop... Primary Periton... | Mind-body resil... Music therapy Propranolol Etodolac | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer | NCT02788708 | Fallopian Tube ... Recurrent Ovari... Primary Periton... Recurrent Endom... | Lenvatinib Mesy... Paclitaxel Pharmacological... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Intraperitoneal Paclitaxel and Carboplatin in the Treatment of Women With Carcinoma of Mullerian Origin | NCT00181701 | Ovarian Carcino... | Paclitaxel Carboplatin | 18 Years - | Massachusetts General Hospital | |
| Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) | NCT02859038 | Epithelial Ovar... Fallopian Tube ... Primary Periton... | Upfront cytored... Interval debulk... | 18 Years - | Shanghai Gynecologic Oncology Group | |
| Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery | NCT03373058 | Epithelial Ovar... Fallopian Tube ... Primary Periton... | Hyperthermic In... cytoreductive s... adjuvant chemot... | 18 Years - 70 Years | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | |
| Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients | NCT01308944 | Invasive Epithe... Primary Periton... Fallopian Tube ... | Propranolol | 18 Years - | Washington University School of Medicine | |
| Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma | NCT05537844 | Ovarian Cancer High Grade Sero... Carcinosarcoma,... Fallopian Tube ... Primary Periton... BRCA1 Mutation BRCA2 Mutation | 16 Years - | Cancer Research UK, Glasgow | ||
| Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer | NCT01442051 | Epithelial Ovar... Fallopian Tube ... Primary Periton... | Acute Normovole... | 18 Years - 69 Years | Memorial Sloan Kettering Cancer Center | |
| A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma | NCT00082212 | Ovarian Cancer | Cetuximab | 18 Years - | Eli Lilly and Company | |
| Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma | NCT00868192 | Ovarian Carcino... Primary Periton... | Pemetrexed Bevacizumab | 18 Years - | Washington University School of Medicine | |
| A Study of CDX-585 in Patients With Advanced Malignancies | NCT05788484 | Non-small Cell ... Gastric Cancer Head and Neck C... Ovarian Cancer Primary Periton... Fallopian Tube ... Bladder Urothel... Colorectal Canc... Esophageal Canc... Hepatic Cancer Renal Cell Carc... Cholangiocarcin... Pancreatic Canc... Other Solid Tum... | CDX-585 | 18 Years - | Celldex Therapeutics | |
| A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | NCT03824704 | Epithelial Ovar... Fallopian Tube ... Primary Periton... High Grade Sero... Endometrioid Ad... | Rucaparib Nivolumab | 18 Years - | pharmaand GmbH | |
| HIPEC After Initial CRS in Patients Who Have Received NACT | NCT03540017 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Cisplatin | 18 Years - 85 Years | Northwell Health | |
| A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies | NCT04440943 | Non-small Cell ... Breast Cancer Gastric Cancer Renal Cell Carc... Ovarian Cancer Primary Periton... Fallopian Tube ... Cholangiocarcin... Bladder Urothel... MSI-H Colorecta... Esophageal Canc... Hepatic Cancer Head and Neck C... Other Solid Tum... | CDX-527 | 18 Years - | Celldex Therapeutics | |
| Intraperitoneal Paclitaxel and Carboplatin in the Treatment of Women With Carcinoma of Mullerian Origin | NCT00181701 | Ovarian Carcino... | Paclitaxel Carboplatin | 18 Years - | Massachusetts General Hospital | |
| Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer | NCT00352300 | Fallopian Tube ... Infectious Diso... Neutropenia Ovarian Carcino... Primary Periton... Stage III Ovari... Stage IV Ovaria... | Adjuvant Therap... Carboplatin Paclitaxel Pegfilgrastim | 18 Years - | GOG Foundation | |
| Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199 | NCT01445275 | Fallopian Tube ... Hereditary Brea... Ovarian Carcino... Primary Periton... | Evaluation of C... Medical Chart R... Study of Socioe... | 30 Years - | GOG Foundation | |
| Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | NCT01295489 | Fallopian Tube ... Ovarian Carcino... Primary Periton... | Laboratory Biom... | 18 Years - | GOG Foundation | |
| Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer | NCT00511992 | Advanced Ovaria... Primary Periton... Ovarian Carcino... | Avastin Paclitaxel Cisplatin | 18 Years - | University of Oklahoma | |
| Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer | NCT03297489 | Fallopian Tube ... Primary Periton... Stage I Ovarian... Stage IA Ovaria... Stage IB Ovaria... Stage IC Ovaria... Stage II Ovaria... Stage IIA Ovari... Stage IIB Ovari... Stage IIC Ovari... Stage III Ovari... Stage IIIA Ovar... Stage IIIB Ovar... Stage IIIC Ovar... Stage IV Ovaria... | Diagnostic Micr... Fluorescein Sod... Laboratory Biom... | 18 Years - | Roswell Park Cancer Institute | |
| Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for Advanced or Recurrent Disease | NCT01588522 | Breast Cancer Cervical Cancer Endometrial Can... Ovarian Cancer Primary Periton... Bone Sarcoma Cancer Solid Tumor | compound 31543 ... | 18 Years - | Berg, LLC | |
| Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma | NCT01381861 | Recurrent Ovari... Fallopian Tube ... Primary Periton... | Carotuximab (TR... | 18 Years - | Tracon Pharmaceuticals Inc. | |
| The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer | NCT03921658 | Ovarian Cancer Fallopian Tube ... Primary Periton... | 18 Years - | University of Minnesota | ||
| BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas | NCT03355976 | Ovarian Cancer Fallopian Tube ... Primary Periton... Extra Renal Ori... Clear Cell Aden... | Nivolumab Ipilimumab | 18 Years - | Brown University | |
| A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer | NCT05198804 | Ovarian Cancer Platinum-resist... Primary Periton... Fallopian Tube ... | ZN-c3 Niraparib | 18 Years - | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | |
| Study of INCB123667 in Subjects With Advanced Solid Tumors | NCT05238922 | Solid Tumors | INCB0123667 | 18 Years - | Incyte Corporation | |
| Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199 | NCT01445275 | Fallopian Tube ... Hereditary Brea... Ovarian Carcino... Primary Periton... | Evaluation of C... Medical Chart R... Study of Socioe... | 30 Years - | GOG Foundation | |
| Study of INCB123667 in Subjects With Advanced Solid Tumors | NCT05238922 | Solid Tumors | INCB0123667 | 18 Years - | Incyte Corporation | |
| First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | NCT01097746 | Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... FIGO Stage III ... FIGO Stage IIIA... FIGO Stage IIIA... FIGO Stage IIIA... FIGO Stage IIIA... FIGO Stage IIIA... FIGO Stage IIIB... FIGO Stage IIIC... FIGO Stage IVA ... FIGO Stage IVB ... Malignant Ovari... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Primary Periton... | Bevacizumab Carboplatin Paclitaxel | 18 Years - | M.D. Anderson Cancer Center | |
| Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women | NCT01227928 | Neoplasms, Ovar... | Pazopanib Placebo compara... | 18 Years - | GlaxoSmithKline | |
| Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) | NCT03648489 | Ovarian Cancer Ovarian Neoplas... Ovarian Carcino... Ovarian Serous ... Ovarian Endomet... Ovarian Clear C... Fallopian Tube ... Fallopian Tube ... Primary Periton... Primary Periton... | Paclitaxel TAK228 | 18 Years - | Imperial College London | |
| Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer | NCT00511992 | Advanced Ovaria... Primary Periton... Ovarian Carcino... | Avastin Paclitaxel Cisplatin | 18 Years - | University of Oklahoma | |
| Consolidation Whole Abdominal Intensity-Modulated Radiation Therapy (IMRT) in Advanced Ovarian Cancer | NCT01180504 | Ovarian Cancer Tubal Carcinoma Primary Periton... | intensity-modul... | 18 Years - | University Hospital Heidelberg | |
| Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors | NCT05858736 | Melanoma Non Small Cell ... Head and Neck S... High Grade Sero... Primary Periton... Fallopian Tube ... Endometrial Can... Cervical Cancer Renal Cell Carc... Bladder Cancer Esophageal Canc... Gastric Cancer Gastroesophagea... Colorectal Canc... Anal Cancer Hepatocellular ... Bile Duct Cance... | AI-061 | 18 Years - | OncoC4, Inc. | |
| Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients | NCT04375956 | Ovarian Cancer Primary Periton... Fallopian Tube ... | Pembrolizumab | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| A Trial of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent or Persistent Ovarian Cancer | NCT02344095 | Epithelial Ovar... Fallopian Tube ... Primary Periton... | weekly paclitax... weekly cisplati... oncothermia | - | Seoul National University Hospital | |
| CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | NCT00045682 | Primary Periton... Recurrent Ovari... | Paclitaxel Poli... | 18 Years - | GOG Foundation | |
| A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer | NCT05200364 | Ovarian Cancer Ovarian Carcino... Ovary Cancer Fallopian Tube ... Primary Periton... | STRO-002 Bevacizumab | 18 Years - | Sutro Biopharma, Inc. | |
| Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers | NCT03604653 | Stomach Cancer Colorectal Canc... Appendiceal Can... Ovarian Cancer Uterine Cancer Cervical Cancer Fallopian Tube ... Primary Periton... | HIPEC Mitomycin c CDDP 50 CDDP 75 Doxorubicin | 18 Years - | Holy Name Medical Center, Inc. | |
| Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers | NCT03748186 | Ovarian Cancer Ovarian Carcino... Ovary Cancer Endometrial Can... Endometrioid Ad... Fallopian Tube ... Primary Periton... | STRO-002 | 18 Years - | Sutro Biopharma, Inc. | |
| Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer | NCT04406623 | Ovarian Cancer Fallopian Tube ... Primary Periton... | SL-172154 | 18 Years - | Shattuck Labs, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
